

# James W Rocco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/149210/publications.pdf>

Version: 2024-02-01

23  
papers

2,488  
citations

586496

16  
h-index

799663

21  
g-index

23  
all docs

23  
docs citations

23  
times ranked

5961  
citing authors

#	ARTICLE	IF	CITATIONS
1	ER $\alpha$ : A biomarker and treatment target for oropharyngeal cancer?. Oral Oncology, 2022, 124, 105637.	0.8	0
2	Predictors of survival following carotid blowout syndrome. Oral Oncology, 2022, 125, 105723.	0.8	1
3	The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma. Oral Oncology, 2022, 126, 105776.	0.8	22
4	Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2022, 28, 2329-2338.	3.2	31
5	Outcomes with culture-directed antibiotics following microvascular free tissue reconstruction for osteonecrosis of the jaw. Oral Oncology, 2022, 130, 105878.	0.8	3
6	Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers, 2021, 13, 1180.	1.7	29
7	A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy. Oral Oncology, 2021, 120, 105421.	0.8	5
8	National treatment trends in human papillomavirus $\alpha$ positive oropharyngeal squamous cell carcinoma. Cancer, 2020, 126, 1295-1305.	2.0	25
9	Predictors of Postoperative Radiation Following Laser Resection in Early-Stage Glottic Cancer. Otolaryngology - Head and Neck Surgery, 2020, 163, 1218-1225.	1.1	3
10	Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma. Cancer, 2020, 126, 1895-1904.	2.0	11
11	Respiratory and pulmonary complications in head and neck cancer patients: Evidence $\alpha$ based review for the COVID $\alpha$ 19 era. Head and Neck, 2020, 42, 1218-1226.	0.9	26
12	Margin Analysis in Head and Neck Cancer: State of the Art and Future Directions. Annals of Surgical Oncology, 2019, 26, 4070-4080.	0.7	37
13	Elective neck dissection for salvage laryngectomy: A systematic review and meta-analysis. Oral Oncology, 2019, 96, 97-104.	0.8	23
14	Risk Factors Associated With Postoperative Delirium in Patients Undergoing Head and Neck Free Flap Reconstruction. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 216.	1.2	39
15	Supine positioning for the subscapular system of flaps: A pictorial essay. Head and Neck, 2018, 40, 1068-1072.	0.9	18
16	Predictors of Complications in Patients Receiving Head and Neck Free Flap Reconstructive Procedures. Otolaryngology - Head and Neck Surgery, 2018, 158, 839-847.	1.1	61
17	Quality Indicators: Measurement and Predictors in Head and Neck Cancer Free Flap Patients. Otolaryngology - Head and Neck Surgery, 2018, 158, 265-272.	1.1	24
18	Appraisal of the AJCC 8th edition pathologic staging modifications for HPV $\alpha$ positive oropharyngeal cancer, a study of the National Cancer Data Base. Oral Oncology, 2017, 73, 152-159.	0.8	70

#	ARTICLE	IF	CITATIONS
19	Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. <i>Cell</i> , 2017, 171, 1611-1624.e24.	13.5	1,656
20	The challenges of tumor genetic diversity. <i>Cancer</i> , 2017, 123, 917-927.	2.0	67
21	Intra-tumor heterogeneity in head and neck cancer and its clinical implications. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2016, 2, 60-67.	0.7	48
22	Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. <i>PLoS Medicine</i> , 2015, 12, e1001786.	3.9	244
23	Molecular Aspects of Head and Neck Cancer Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 971-992.	0.9	45